Stephen J. Keely
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen J. Keely has a total of 523 co-authors. Here are the top co-authors by number of shared publications:
Kim E. Barrett
Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California, USA; Department of Physiology and Membrane Biology, School of Medicine, University of California Davis, Davis, California, USA
12 shared publicationsMagdalena S. Mroz
RCSI University of Medicine and Health Sciences
9 shared publications- Kim E. Barrett
Department of Physiology and Membrane Biology University of California Davis School of Medicine Sacramento CA USA
8 shared publications - Alan William Baird
University College Dublin, Belfield, Dublin, Ireland
7 shared publications Alan F. Hofmann
Department of Medicine, University of California, San Diego, USA
6 shared publicationsFrank E. Murray
Department of Gastroenterology, Beaumont Hospital, Dublin, Ireland
6 shared publications
Latest Publications
- 1 February 2026
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 330 (2) , G110-G122
The secondary bile acid, lithocholic acid, inhibits cystic fibrosis transmembrane conductance regulator expression and activity in colonic epithelial cells
This study reveals a previously unrecognized role for lithocholic acid (LCA) in chronically suppressing colonic epithelial chloride secretion. We demonstrate a genomic mechanism of action for LCA that is likely mediated by FXR-induced downregulation of CFTR expression and function. These findings highlight LCA as a key modulator of intestinal fluid and electrolyte transport and underline the therapeutic potential of targeting bile acids and their receptors for the treatment of diarrheal diseases.
- 1 February 2026
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 330 (2) , G110-G122
The secondary bile acid, lithocholic acid, inhibits cystic fibrosis transmembrane conductance regulator expression and activity in colonic epithelial cells
This study reveals a previously unrecognized role for lithocholic acid (LCA) in chronically suppressing colonic epithelial chloride secretion. We demonstrate a genomic mechanism of action for LCA that is likely mediated by FXR-induced downregulation of CFTR expression and function. These findings highlight LCA as a key modulator of intestinal fluid and electrolyte transport and underline the therapeutic potential of targeting bile acids and their receptors for the treatment of diarrheal diseases.
- 2 November 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (24) , 7641-7643
The role of the gut in obesity – new insights into the physiology of therapeutic approaches
- 2 November 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (24) , 7641-7643
The role of the gut in obesity – new insights into the physiology of therapeutic approaches
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 329 (2) , G261-G269
Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function
These studies demonstrate for the first time that FXR activation inhibits cytokine-induced necroptosis in vitro, an effect that may underlie protection against dysregulated barrier function in the setting of intestinal inflammation. These data support the potential for targeting FXR to promote epithelial barrier function in treatment of IBD.
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 329 (2) , G261-G269
Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function
These studies demonstrate for the first time that FXR activation inhibits cytokine-induced necroptosis in vitro, an effect that may underlie protection against dysregulated barrier function in the setting of intestinal inflammation. These data support the potential for targeting FXR to promote epithelial barrier function in treatment of IBD.
- 22 January 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (4) , 797-807
From human to superhuman: the impact of the microbiome on physiology
The complex microbial community residing in the human gut has long been understood to regulate gastrointestinal physiology and to participate in digestive diseases, but its extraintestinal actions and influences are increasingly recognized. This article discusses bidirectional interactions between the gut microbiome and athletic performance, metabolism, longevity and the ability of the gut–brain axis to influence cognitive function and mental health. image
- 22 January 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (4) , 797-807
From human to superhuman: the impact of the microbiome on physiology
The complex microbial community residing in the human gut has long been understood to regulate gastrointestinal physiology and to participate in digestive diseases, but its extraintestinal actions and influences are increasingly recognized. This article discusses bidirectional interactions between the gut microbiome and athletic performance, metabolism, longevity and the ability of the gut–brain axis to influence cognitive function and mental health. image
- 1 November 2023
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 325 (5) , G446-G452
Farnesoid X receptor enhances epithelial ACE2 expression and inhibits virally induced IL-6 secretion: implications for intestinal symptoms of SARS-CoV-2
Activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), specifically upregulates ACE2 expression in undifferentiated colonic epithelial cells and inhibits virus-induced proinflammatory cytokine release. By virtue of these actions FXR represents a promising target for the development of new approaches to prevent intestinal manifestations of SARS-CoV-2 infection.
- 1 November 2023
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 325 (5) , G446-G452
Farnesoid X receptor enhances epithelial ACE2 expression and inhibits virally induced IL-6 secretion: implications for intestinal symptoms of SARS-CoV-2
Activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), specifically upregulates ACE2 expression in undifferentiated colonic epithelial cells and inhibits virus-induced proinflammatory cytokine release. By virtue of these actions FXR represents a promising target for the development of new approaches to prevent intestinal manifestations of SARS-CoV-2 infection.
- Open Access
- 6 October 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (11) , 102569
Pentacyclic triterpenes modulate farnesoid X receptor expression in colonic epithelial cells: Implications for colonic secretory function
- 6 October 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (11) , 102569
Open AccessPentacyclic triterpenes modulate farnesoid X receptor expression in colonic epithelial cells: Implications for colonic secretory function
- 1 July 2021
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1863 (7) , 183619
Expression, regulation and function of Aquaporin-3 in colonic epithelial cells
- 1 July 2021
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1863 (7) , 183619
Expression, regulation and function of Aquaporin-3 in colonic epithelial cells
- Open Access
- 31 March 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (4) , 732
Functional and Phylogenetic Diversity of BSH and PVA Enzymes
Bile salt hydrolase (BSH) and penicillin V acylase (PVA) are related enzymes that are classified as choloylglycine hydrolases (CGH). BSH enzymes have attracted significant interest for their ability to modulate the composition of the bile acid pool, alter bile acid signaling events mediated by the host bile acid receptors FXR and TGR5 and influence cholesterol homeostasis in the host, while PVA enzymes have been widely utilised in an industrial capacity in the production of semi-synthetic antibiotics. The similarities between BSH and PVA enzymes suggest common evolution of these enzymes and shared mechanisms for substrate binding and catalysis. Here, we compare BSH and PVA through analysis of the distribution, phylogeny and biochemistry of these microbial enzymes. The development of new annotation approaches based upon functional enzyme analyses and the potential implications of BSH enzymes for host health are discussed.
- 31 March 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (4) , 732
Open AccessFunctional and Phylogenetic Diversity of BSH and PVA Enzymes
Bile salt hydrolase (BSH) and penicillin V acylase (PVA) are related enzymes that are classified as choloylglycine hydrolases (CGH). BSH enzymes have attracted significant interest for their ability to modulate the composition of the bile acid pool, alter bile acid signaling events mediated by the host bile acid receptors FXR and TGR5 and influence cholesterol homeostasis in the host, while PVA enzymes have been widely utilised in an industrial capacity in the production of semi-synthetic antibiotics. The similarities between BSH and PVA enzymes suggest common evolution of these enzymes and shared mechanisms for substrate binding and catalysis. Here, we compare BSH and PVA through analysis of the distribution, phylogeny and biochemistry of these microbial enzymes. The development of new annotation approaches based upon functional enzyme analyses and the potential implications of BSH enzymes for host health are discussed.
- Open Access
- 19 June 2020
- Published by Wiley in Physiological Reports
- Vol. 8 (12) , e14456
The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis
Bacterial metabolism of UDCA to LCA protects against DSS‐induced colonic inflammation by preventing epithelial apoptosis and promoting barrier function. In conditions of IBD, increased production of ...
- 19 June 2020
- Published by Wiley in Physiological Reports
- Vol. 8 (12) , e14456
Open AccessThe secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis
Bacterial metabolism of UDCA to LCA protects against DSS‐induced colonic inflammation by preventing epithelial apoptosis and promoting barrier function. In conditions of IBD, increased production of ...